Abstract
Abstract Date Presented 04/21/2023 This study identified unique OT needs of older adults with acute myeloid leukemia (AML) receiving oral venetoclax and infusional hypomethalating agent (VEN + HMA) therapy. A battery of tests performed on 19 older adults in the early stages of chemotherapy suggest that grip strength and mobility decline and the need for more nuanced evaluation of cognition. We found careful evaluation was important to understand cognitive and physical impairments in the context of meaningful occupational challenges. Primary Author and Speaker: Farrell Leigh Wiggins Additional Authors and Speakers: Alexis Petteway Contributing Authors: Mackenzi Pergolotti, Todd Schwartz, Zachary Ripberger, Susan Coppola, Ashley Bryant, Ya-Ning Chan
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
